Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines
- PMID: 16896579
- DOI: 10.1007/s15010-006-6604-4
Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines
Abstract
Objectives: This large-scale study provides up-to-date estimates of Varicella zoster virus (VZV) age-specific seroprevalence and characteristics of VZV transmission in a representative sample of the Israeli population.
Methods: In 2000-2001, 1,642 sera collected from an agestratified general population sample were tested for VZV antibodies using an indirect IgG ELISA system.
Results: The age-weighted VZV overall estimate was 90.2%. Seropositivity increased rapidly with age, from 68.9% at age 4 to 94.4% at age 7 and 96.6% at age 12 years. The highest force of infection was in the 4-5 years age group (0.548 per susceptible year) followed by the 6-9 years age group. Multivariate analysis revealed that VZV seroprevalence estimates were significantly associated with age and place of origin. The highest seroprevalence estimate was found among subjects of Eastern origin.
Conclusions: The seroepidemiology of VZV in Israel shows a pattern corresponding to that described for developed European countries. This study indicates that the highest force of infection is in pre-school children. Knowledge of pre-vaccination seroepidemiology is important to evaluate the effect of vaccination programs on the epidemiology of the disease.
Similar articles
-
Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey.Health Policy. 2005 Apr;72(1):119-24. doi: 10.1016/j.healthpol.2004.03.008. Health Policy. 2005. PMID: 15760704
-
Analysis of factors associated with varicella-zoster virus susceptibility among children 0-12 years old in Taiwan.Med Mal Infect. 2007 Apr;37(4):222-8. doi: 10.1016/j.medmal.2006.10.013. Epub 2007 Mar 26. Med Mal Infect. 2007. PMID: 17368781
-
Immunity to varicella zoster virus among young adults: a decline prior to widespread uptake of varicella vaccines.Infection. 2008 Mar;36(2):130-4. doi: 10.1007/s15010-007-7192-7. Epub 2008 Mar 31. Infection. 2008. PMID: 18379727
-
The safety profile of varicella vaccine: a 10-year review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. J Infect Dis. 2008. PMID: 18419392 Review.
-
The effect of vaccination on the epidemiology of varicella zoster virus.J Infect. 2002 May;44(4):211-9. doi: 10.1053/jinf.2002.0988. J Infect. 2002. PMID: 12099726 Review.
Cited by
-
Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain).Med Microbiol Immunol. 2008 Sep;197(3):329-33. doi: 10.1007/s00430-007-0064-z. Epub 2007 Nov 15. Med Microbiol Immunol. 2008. PMID: 18004592
-
Systematic analysis of infectious disease outcomes by age shows lowest severity in school-age children.Sci Data. 2020 Oct 15;7(1):329. doi: 10.1038/s41597-020-00668-y. Sci Data. 2020. PMID: 33057040 Free PMC article.
-
Seroprevalence of varicella-zoster virus among pregnant women in Fayoum Governorate, Egypt.J Egypt Public Health Assoc. 2019;94(1):2. doi: 10.1186/s42506-018-0002-5. Epub 2019 Jan 7. J Egypt Public Health Assoc. 2019. PMID: 30686830 Free PMC article.
-
Spatial and temporal distribution of West Nile virus in horses in Israel (1997-2013)--from endemic to epidemics.PLoS One. 2014 Nov 17;9(11):e113149. doi: 10.1371/journal.pone.0113149. eCollection 2014. PLoS One. 2014. PMID: 25402217 Free PMC article.
-
Sero-Prevalence of Antibodies against Varicella Zoster Virus in Children under Seven-Years Old in 2012 in Tehran, Iran.Iran J Public Health. 2014 Nov;43(11):1569-75. Iran J Public Health. 2014. PMID: 26060726 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical